Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer

Fabio Y. Moraes; Luke A. Perry; Jahan C. Penny-Dimri; Dhruvesh Ramson; Tiago B. de Castria; Rayleen V. Bowman; Fábio N. Santos; Kwun M. Fong; Rachel Riera

doi:10.1002/14651858.CD012644

Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer

Fabio Y. Moraes, Luke A. Perry, Jahan C. Penny-Dimri, Dhruvesh Ramson, Tiago B. de Castria, Rayleen V. Bowman, Fábio N. Santos, Kwun M. Fong, Rachel Riera

Surgery Monash Health

Research output: Contribution to journal › Article › Research › peer-review

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) compared with standard chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer (NSCLC).

Original language	English
Article number	CD012644
Number of pages	14
Journal	Cochrane Database of Systematic Reviews
Volume	2017
Issue number	4
DOIs	https://doi.org/10.1002/14651858.CD012644
Publication status	Published - 26 Apr 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.CD012644

292418512-oaFinal published version, 225 KB

Cite this

Moraes, F. Y., Perry, L. A., Penny-Dimri, J. C., Ramson, D., de Castria, T. B., Bowman, R. V., Santos, F. N., Fong, K. M., & Riera, R. (2017). Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. Cochrane Database of Systematic Reviews, 2017(4), [CD012644]. https://doi.org/10.1002/14651858.CD012644

Moraes, Fabio Y. ; Perry, Luke A. ; Penny-Dimri, Jahan C. ; Ramson, Dhruvesh ; de Castria, Tiago B. ; Bowman, Rayleen V. ; Santos, Fábio N. ; Fong, Kwun M. ; Riera, Rachel. / Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. In: Cochrane Database of Systematic Reviews. 2017 ; Vol. 2017, No. 4.

@article{6cb22929567c4b0984a3f600fea46487,

title = "Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer",

abstract = "This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) compared with standard chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer (NSCLC).",

author = "Moraes, {Fabio Y.} and Perry, {Luke A.} and Penny-Dimri, {Jahan C.} and Dhruvesh Ramson and {de Castria}, {Tiago B.} and Bowman, {Rayleen V.} and Santos, {F{\'a}bio N.} and Fong, {Kwun M.} and Rachel Riera",

year = "2017",

month = apr,

day = "26",

doi = "10.1002/14651858.CD012644",

language = "English",

volume = "2017",

journal = "Cochrane Database of Systematic Reviews",

issn = "1469-493X",

publisher = "John Wiley & Sons",

number = "4",

}

Moraes, FY, Perry, LA, Penny-Dimri, JC, Ramson, D, de Castria, TB, Bowman, RV, Santos, FN, Fong, KM & Riera, R 2017, 'Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer', Cochrane Database of Systematic Reviews, vol. 2017, no. 4, CD012644. https://doi.org/10.1002/14651858.CD012644

Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer. / Moraes, Fabio Y.; Perry, Luke A.; Penny-Dimri, Jahan C.; Ramson, Dhruvesh; de Castria, Tiago B.; Bowman, Rayleen V.; Santos, Fábio N.; Fong, Kwun M.; Riera, Rachel.

In: Cochrane Database of Systematic Reviews, Vol. 2017, No. 4, CD012644, 26.04.2017.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer

AU - Moraes, Fabio Y.

AU - Perry, Luke A.

AU - Penny-Dimri, Jahan C.

AU - Ramson, Dhruvesh

AU - de Castria, Tiago B.

AU - Bowman, Rayleen V.

AU - Santos, Fábio N.

AU - Fong, Kwun M.

AU - Riera, Rachel

PY - 2017/4/26

Y1 - 2017/4/26

N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) compared with standard chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer (NSCLC).

AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the effectiveness and safety of immune checkpoint inhibitors (anti PD-1 or anti PD-L1) compared with standard chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer (NSCLC).

UR - http://www.scopus.com/inward/record.url?scp=85018639834&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD012644

DO - 10.1002/14651858.CD012644

M3 - Article

AN - SCOPUS:85018639834

VL - 2017

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 4

M1 - CD012644

ER -

Immune checkpoint inhibitors (anti PD-1 or anti PD-L1) versus chemotherapy for second- or third-line treatment of metastatic non-small cell lung cancer

Abstract

UN SDGs

Access to Document

Other files and links

Cite this